Furthermore, the use of 68Ga-PSMA PET/CT as a potential biomarker for the in vivo assessment of PSMA expression could provide reliable information on prognosis and prediction of response to different antitumor agents in advanced PCa, as recently seen for 18F-choline PET/CT30–32, opening up new avenues of research into PSMA pathological-clinical correlations. Here, FOLH1 is linked to posterior cortical atrophy.